Well-organized Patient Assistance Programs (PAPs) facilitate coordinated product and patient journeys, including high-touch care, a smart financial strategy, and prompt medication access. Watch our latest video to learn what UBC is doing throughout every step of our PAPs to support manufacturers and patients alike.
As the specialty market continues to grow, so do the market access challenges associated with these products requiring high-touch services.
Compassion is good business. That’s why we put the patient at the center of all of our commercial services, including Reimbursement Hubs.
Ahead of the staggering changes brought about by the Affordable Care Act (ACA), many predicted that the need for manufacturer-funded Patient Assistance Programs would decline as patients received coverage from new government sources. Now that we are well into the ACA’s implementation, it’s clear how healthcare reform is impacting PAPs. Our latest blog post examines what changed and what hasn’t.
At last week’s 15th Annual Patient Assistance and Access Programs conference, I joined more than 400 industry experts to discuss the changing landscape of patient assistance. This is a hot topic that we’ve discussed here on the blog. It will continue to receive attention as the regulations are finalized.
There’s a lot of ambiguity around how the government is going to view the private and public exchanges. An OIG opinion providing guidance on whether these plans will be viewed as public versus private plans could have far-reaching implications for how manufacturers provide patient assistance. If we look at some of the OIG guidance offered around Medicare Part D plans and the potential for anti-kickback penalties when offering direct assistance to these beneficiaries, we can start to hypothesize about some of the challenges pharmaceutical manufacturers will face.